Organic Process Research & Development 2009, 13, 710–715
A Facile, One-Pot Synthesis of Lacidipine Using in Situ Generation of Wittig
†
Intermediates
,‡
‡
‡
§
‡
V. V. N. K. V. Prasada Raju,* Vedantham Ravindra, Vijayavitthal T. Mathad, P. K. Dubey, and Padi Pratap Reddy
Department of Research and DeVelopment, Integrated Product DeVelopment, InnoVation Plaza, Dr. Reddy’s Laboratories Ltd.,
SurVey Nos.42, 45, 46, and 54, Bachupally, Qutubullapur, R. R. District - 500 072, A.P, India, and Department of Chemistry,
Jawaharlal Nehru Technological UniVersity, Kukatpally, Hyderabad - 500 072, Andhra Pradesh, India
Abstract:
subsequent trituration of the obtained oil with petroleum ether
gave crude lacidipine, which was crystallized to give pure 1
with an overall yield of 23.7% (starting from 4, Scheme. 1).
Alternatively, condensation of 6 and 7 in acetic acid at room
temperature followed by column chromatography purification
provided compound 1 with an overall yield of 5.4% (starting
from 4).
An improved, one-pot process for the preparation of lacidipine
(1) via an efficient in situ generation of Wittig intermediates is
reported. Generation of ylide (4) by dehydrobromination of
phosphonium salt (3) followed by in situ condensation of 4 with
o-phthalaldehyde (5) to yield corresponding olefin (6) and its
subsequent reaction with crotonate derivative (7) in the same pot
furnished the drug substance 1 with an overall yield of about 51%
over the reported yield of about 24% starting from the corre-
sponding ylide. The present work overcomes the challenges
associated with prior art processes such as chromatographic
purifications, handling of unstable intermediates, and formation
of byproducts as potential impurities. The interesting insights on
the safety aspects of the process, drawn through calorimetric
studies, rendered the successful implementation of the process at
manufacturing facility.
The challenges encountered while following this reported
process were: (a) handling of unstable Wittig intermediate 4,
(
(
b) formation of potential impurities such as vinyl benzaldehyde
6a) and dimer (6b), (c) classical problem of removing the
byproduct Ph PO (6c), (d) use of column chromatography for
3
isolation and purification, and (e) low overall yield (about 24%).
The reported procedures as described above are either lengthy
3
or used hazardous and/or relatively expensive chemicals.
Herein, we report an improved, facile, and one-pot process for
the preparation of 1 by surmounting the aforesaid challenges.
Our approach was aimed to avoid the isolation and purification
of critical intermediates 4 and 6 by designing ylide generation,
olefination, and condensation with amino crotonate 7 in single
pot. In this new process, the potential impurities, byproduct,
and unreacted intermediates are efficiently controlled through
proper understanding of process parameters responsible for
impurity formation coupled with an efficient workup process.
The process was scaled up successfully by assessing the process
safety of optimized process through reaction calorimetry.
Introduction
(E)-4-[2-[3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl]phenyl]-
1
,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl
1
ester (lacidipine, 1), a vascular-selective calcium antagonist
with a potent and long-lasting antihypertensive activity is
marketed under the brand names, Lacipil and Motens. The first
2
3
4
reported synthesis of 1 involved the reaction of ylide 4 with
o-phthalaldehyde 5 in dichloromethane to give crude olefin 6
as yellow oil, which was purified by column chromatography
using petroleum ether and diethyl ether before it was reacted
with amino crotonate 7 in ethanol in the presence of trifluoro-
acetic acid at -10 °C for 1.5 h. Quenching the mass into an
aqueous solution of sodium bicarbonate and extracting 1 in tert-
butyl methyl ether, concentration of the organic layer, and
Results and Discussion
Identification of Challenges in the Process Development
of 1 Using the Reported Synthesis (Scheme 1). Phosphonium
5
bromide (3) when treated with an aqueous solution of sodium
hydroxide, underwent rapid dehydrobromination to yield ylide
4
along with the formation of impurities due to its instability
under the reaction conditions. It was also observed that
subsequent reaction of 4 with 5 led to the predominant formation
of decarboxylated impurity 3a, which in turn will further react
with 5, resulting in vinylbenzaldehye (6a) as an impurity.
Formation of dimer 6b is attributed to a lack of chemoselectivity
as there are two equivalent formyl groups present in o-
phthalaldehyde 5. The dimer impurity 6b was independently
synthesized by reacting 5 with an excess of 3 in the presence
of sodium hydroxide using dichloromethane or 1,4-dioxane as
†
Dr. Reddy’s Communication no. IPDO IPM-00171.
To whom correspondence should be addressed. E-mail: prasadvvnkv@
*
drreddys.com. Fax: 914044346840. Telephone: 9989997170.
‡
Dr. Reddy’s Laboratories Ltd.
Jawaharlal Nehru Technological University.
§
(
1) (a) Tcherdakoff, P.; Mallion, J. M. J. CardioVasc. Pharmacol. 1995,
2
5, S27. (b) Lee, C. R.; Bryson, H. M. Drugs 1994, 48, 274. (c)
McCormack, P. L.; Wagstaff, A. J. Drugs 2003, 63, 2327. (d) Haller,
H.; Cosentino, F.; Liischer, T. F. Drugs RD 2002, 3, 311.
2) See http://thomsonpharma.com/copyright.
3) (a) Claudio Semeraro, B.; Dino Micheli, M.; Daniele, P.; Giovanni,
G.; Allan, D. B. DE Patent 3529997, 1986; U.S. Patent 4,801,599,
(
(
1
989. (b) Safar, M.; Bons, J.; Georges, D.; Cournot, A.; Duchier, J.
Clin. Pharmacol. Ther. 1989, 46, 94. (c) Claudio Semeraro, B.; Dino
Micheli, M.; Daniele, P.; Giovanni, G.; Allan, D. B. GB Patent
(5) (a) Niedercorn, F.; Ledon, H.; Tkatchenko, I. New J. Chem. 1988,
12, 897. (b) Cabral dos Santos, L.; Bahlaouan, Z.; El Kassimi, K.;
Troufflard, C.; Hendra, F.; Delarue Cochin, S.; Zahouily, M.; Cave,
C.; Joseph, D. Heterocycles 2007, 73, 751. (c) Maaryanoff, B. E.;
Reitz, A. B. Chem. ReV. 1989, 89, 863.
2
164336 A, 1986.
(
4) (a) Miyano, M.; Dorn, C. R. J. Org. Chem. 1972, 37, 1818. (b) Hamper,
B. C. J. Org. Chem. 1988, 53, 5558.
7
10
•
Vol. 13, No. 4, 2009 / Organic Process Research & Development
10.1021/op900055u CCC: $40.75 2009 American Chemical Society
Published on Web 05/19/2009